Atypical Endometrial Hyperplasia Clinical Trial
Official title:
Operational Hysteroscopy Versus Traditional Surgery: Costs and Health Benefits
Verified date | June 2007 |
Source | IRCCS Burlo Garofolo |
Contact | n/a |
Is FDA regulated | No |
Health authority | Italy: Ministry of Health |
Study type | Interventional |
The study aims to evaluate the long-term efficacy and prognosis of hysteroscopic resection and coagulation of the base of endometrial polyps with focal atypia in fertile women.
Status | Completed |
Enrollment | 21 |
Est. completion date | March 2007 |
Est. primary completion date | March 2007 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 25 Years to 50 Years |
Eligibility |
Inclusion Criteria: - women in fertile age desiring to preserve their uterus - atypical polyps, without atypia in the base. The hysteroscopic and histologic criteria for inclusion in the study were: proliferative, secretive, dysfunctional endometrium or simple hyperplasia in 4 random biopsies. Exclusion Criteria: - women with adenomatous or atypical hyperplasia in the random biopsies |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Italy | Institute of Child Health, IRCCS Burlo Garofolo | Trieste | Friuli Venezia Giulia |
Lead Sponsor | Collaborator |
---|---|
IRCCS Burlo Garofolo |
Italy,
Scrimin F, Wiesenfeld U, Candiotto A, Inglese S, Ronfani L, Guaschino S. Resectoscopic treatment of atypical endometrial polyps in fertile women. Am J Obstet Gynecol. 2008 Oct;199(4):365.e1-3. doi: 10.1016/j.ajog.2008.03.041. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Efficacy and prognosis of hysteroscopic resection of atypical polyps in terms of appearance of endometrial cancer or recurrence of atypical endometrial lesions | Five years | Yes | |
Secondary | Recurrence rate of polyp in the two groups | Five years | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02397083 -
Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer
|
Phase 2 | |
Recruiting |
NCT05647109 -
Patient-derived Tumor-like Cell Clusters Predict Progesterone Sensitivity in Patients With Early Endometrial Cancer
|
||
Completed |
NCT04491682 -
Megestrol Acetate Plus Rosuvastatin in Young Women With Atypical Endometrial Hyperplasia
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT00788671 -
Levonorgestrel-Releasing Intrauterine System in Treating Patients With Complex Atypical Hyperplasia or Grade I Endometrial Cancer
|
Phase 2 | |
Completed |
NCT04385667 -
LVN- IUS Versus Oral Megesterol Acetate in Treatment of Atypical Endometrial Hyperplasia
|
Phase 2/Phase 3 | |
Withdrawn |
NCT01943058 -
Megestrol Acetate or Levonorgestrel-Releasing Intrauterine System in Treating Patients With Atypical Endometrial Hyperplasia or Endometrial Cancer
|
Phase 2 | |
Withdrawn |
NCT04683237 -
Liraglutide Plus Megestrol Acetate in Endometrial Atypical Hyperplasia
|
Phase 2/Phase 3 | |
Completed |
NCT00483327 -
Management of Atypical Endometrial Hyperplasia and Endometrial Carcinoma Using Megestrol Acetate
|
Phase 2 | |
Recruiting |
NCT05316493 -
Weight Management Plus LNG-IUS/Megestrol Acetate in Endometrial Atypical Hyperplasia
|
Phase 2/Phase 3 | |
Completed |
NCT03241888 -
Megestrol Acetate Plus LNG-IUS in Young Women With Endometrial Atypical Hyperplasia
|
Phase 2/Phase 3 | |
Recruiting |
NCT06379113 -
GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients
|
Phase 2/Phase 3 | |
Recruiting |
NCT05316935 -
GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients
|
Phase 2/Phase 3 | |
Recruiting |
NCT06390904 -
GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Atypical Hyperplasia Patients
|
Phase 2/Phase 3 | |
Recruiting |
NCT05172999 -
Loxenatide Plus LNG-IUS in Endometrial Atypical Hyperplasia
|
Phase 2/Phase 3 | |
Recruiting |
NCT05675787 -
Medroxyprogesterone Acetate Plus Atorvastatin in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia
|
Phase 2 | |
Active, not recruiting |
NCT03671811 -
Megestrol Acetate With or Without Pterostilbene in Treating Patients With Endometrial Cancer Undergoing Hysterectomy
|
Phase 2 | |
Terminated |
NCT04607252 -
Metformin Plus Megestrol Acetate as a Fertility-sparing Treatment in Patients With Atypical Endometrial Hyperplasia
|
Phase 2/Phase 3 | |
Recruiting |
NCT05051722 -
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
|
||
Active, not recruiting |
NCT00892866 -
CA-IX, p16, Proliferative Markers, and HPV in Diagnosing Cervical Lesions in Patients With Abnormal Cervical Cells
|
N/A | |
Recruiting |
NCT03463252 -
Value of LNG-IUS as Fertility-preserving Treatment of EAH and EC
|
Phase 2/Phase 3 |